摘要
目的 研究喉癌病人外周血中期因子 (midkine,MK)水平与喉癌临床特征及预后的关系。方法 采用酶联免疫吸附测定检测喉癌病人及健康体检者 (对照组 )外周血中MK水平 ,通过SPSS软件分析MK与喉癌临床特征及预后的关系。结果 喉癌病人血清MK水平为 (40 0± 2 2 9) pg/ml,对照组为(1 1 8± 97) pg/ml,差异有统计学意义 (P <0 .0 0 1 )。以 30 0 pg/ml为分界值 ,MK阳性率随喉癌进展呈上升趋势 (P <0 .0 1 ) :I期 5 3%(1 0 / 1 9) ,Ⅱ期 6 0 %(1 8/ 30 ) ,Ⅲ期 6 2 %(2 8/ 4 5 ) ,Ⅳ期 75 %(1 5 / 2 0 )。MK水平与T分期成正相关 (P <0 .0 1 )。随访病例 5 8例 ,经Kaplan Meier生存曲线分析 ,5年生存率MK阳性者为 5 3%,阴性者为 77%,差异有统计学意义(P <0 .0 5 )。结论 高水平的MK(≥ 30 0 pg/ml)与不良预后相关。血清MK水平可以作为预测喉癌病人的生存期的一个临床指标。
Objective To evaluate the clinical significance of serum midkine (MK) in patients with laryngeal squamous cell carcinoma (LSCC). Methods Serum MK was measured by enzyme-linked immunosorbent assay in 97 healthy controls and 114 patients with LSCC before surgery. Results MK values in patients with LSCC were significantly higher than those in healthy controls (400±229 pg/ml vs 118±97 pg/ml, P< 0.001). Using 300 pg/ml as the cut-off value, the positive rate of patients with LSCC showed an increasing trend (P< 0.01): 53% (10/19) in stage I, 60% (18/30) in stage Ⅱ, 62% (28/45) in stage Ⅲ, 75% (15/20) in stage Ⅳ. MK values was associated with T staging (P< 0.001). 58 patients were followed up, using Kaplan-Meier survival analysis. The 5-year survival rate was significantly lower in MK positive patients than that in MK negative patients (53% vs 77%, P< 0.05). Conclusion Increased MK in patients with LSCC was associated with poor survival. Serum MK was a prognostic factor for LSCC.
出处
《中国耳鼻咽喉颅底外科杂志》
CAS
2005年第1期14-16,共3页
Chinese Journal of Otorhinolaryngology-skull Base Surgery
关键词
喉肿瘤/死亡率
中期因子
预后
生存分析
Laryngeal neoplasms/mortality
Midkine
Prognosis
Survival analysis
